Green tea EGCG, T cells, and T cell-mediated autoimmune diseases.
ABSTRACT One of the proposed health benefits of consuming green tea is its protective effect on autoimmune diseases. Research on the immunopathogenesis of autoimmune diseases has made significant progression in the past few years and several key concepts have been revised. T cells, particularly CD4(+) T helper (Th) cells, play a key role in mediating many aspects of autoimmune diseases. Upon antigenic stimulation, naïve CD4(+) T cells proliferate and differentiate into different effector subsets. Th1 and Th17 cells are the pro-inflammatory subsets of Th cells responsible for inducing autoimmunity whereas regulatory T cells (Treg) have an antagonistic effect. Green tea and its active ingredient, epigallocatechin-3-gallate (EGCG), have been shown to improve symptoms and reduce the pathology in some animal models of autoimmune diseases. Whether or not EGCG's effect is mediated through its impact on Th17 and Treg development has not been studied. We conducted a series of studies to investigate EGCG's effect on CD4(+) T cell proliferation and differentiation as well as its impact on the development of autoimmune disease. We first observed that EGCG inhibited CD4(+) T cell expansion in response to either polyclonal or antigen specific stimulation. We then determined how EGCG affects naïve CD4(+) T cell differentiation and found that it impeded Th1 and Th17 differentiation and prevented IL-6-induced inhibition on Treg development. We further demonstrated that EGCG inhibited Th1 and Th17 differentiation by downregulating their corresponding transcription factors (STAT1 and T-bet for Th1, and STAT3 and RORγt for Th17). These effects provide further explanation for previous findings that administration of EGCG by gavage to experimental autoimmune encephalomyelitis (EAE) mice, an animal model for human multiple sclerosis (MS), reduced the clinical symptoms, brain pathology, and proliferation and TNF-α production of encephalitogenic T cells. Upon further investigating the working mechanisms for EGCG's protective effect in the EAE model, we showed that dietary EGCG dose-dependently attenuated the disease's severity. This protective effect of EGCG is associated with the suppressed proliferation of autoreactive T cells, reduced production of pro-inflammatory cytokines, decreased Th1 and Th17, and increased Treg populations in lymphoid tissues and central nervous system. EGCG-induced shifts in CD4(+) T cell subsets in EAE mice are accompanied by the corresponding changes in their regulator molecules. Recent studies have also highlighted the critical role of Th17/Treg balance in the pathogenesis of rheumatoid arthritis (RA). EGCG has been shown to be anti-inflammatory and protective in several studies using animal models of inflammatory arthritis, but research, at the best, only to start looking into the mechanisms with a focus on T cells. Overall, future research should fully incorporate the current progress in autoimmunity into the study design to expand the power of evaluating EGCG's efficacy in treating autoimmune diseases. Data from human studies are essentially absent and thus are urgently needed.
- SourceAvailable from: PubMed Central[Show abstract] [Hide abstract]
ABSTRACT: The mechanisms contributing to sarcopenia include reduced satellite cell (myogenic stem cell) function that is impacted by the environment (niche) of these cells. Satellite cell function is affected by oxidative stress, which is elevated in aged muscles, and this along with changes in largely unknown systemic factors, likely contribute to the manner in which satellite cells respond to stressors such as exercise, disuse, or rehabilitation in sarcopenic muscles. Nutritional intervention provides one therapeutic strategy to improve the satellite cell niche and systemic factors, with the goal of improving satellite cell function in aging muscles. Although many elderly persons consume various nutraceuticals with the hope of improving health, most of these compounds have not been thoroughly tested, and the impacts that they might have on sarcopenia and satellite cell function are not clear. This review discusses data pertaining to the satellite cell responses and function in aging skeletal muscle, and the impact that three compounds: resveratrol, green tea catechins, and β-Hydroxy-β-methylbutyrate have on regulating satellite cell function and therefore contributing to reducing sarcopenia or improving muscle mass after disuse in aging. The data suggest that these nutraceutical compounds improve satellite cell function during rehabilitative loading in animal models of aging after disuse (i.e., muscle regeneration). While these compounds have not been rigorously tested in humans, the data from animal models of aging provide a strong basis for conducting additional focused work to determine if these or other nutraceuticals can offset the muscle losses, or improve regeneration in sarcopenic muscles of older humans via improving satellite cell function.Frontiers in Aging Neuroscience 09/2014; 6:246. · 2.84 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Infrasound, a kind of common environmental noise and a major contributor of vibroacoustic disease, can induce the central nervous system (CNS) damage. However, no relevant anti-infrasound drugs have been reported yet. Our recent studies have shown that infrasound resulted in excessive microglial activation rapidly and sequential inflammation, revealing a potential role of microglia in infrasound-induced CNS damage. Epigallocatechin gallate (EGCG), a major bioactive component in green tea, has the capacity of protecting against various neurodegenerative diseases via an anti-inflammatory mechanism. However, it's still unknown to date whether EGCG acts on infrasound-induced microglial activation and neuronal damage. We showed that, after 1-, 2- or 5-day exposure of rats to 16 Hz, 130 dB infrasound (2 h/day), EGCG significantly inhibited infrasound-induced microglial activation in rat hippocampal region, evidenced by reduced expressions of Iba-1 (a marker for microglia) and pro-inflammatory cytokines (IL-1β, IL-6, IL-18 and TNF-α). Moreover, infrasound-induced neuronal apoptosis in rat hippocampi was significantly suppressed by EGCG. EGCG also inhibited infrasound-induced activation of primary microglia in vitro and decreased the levels of pro-inflammatory cytokines in the supernatants of microglial culture, which were toxic to cultured neurons. Furthermore, EGCG attenuated infrasound-induced increases in nuclear NF-κB p65 and phosphorylated IκBα, and ameliorated infrasound-induced decrease in IκB in microglia. Therefore, our study provides the first evidence that EGCG acts against infrasound-induced neuronal impairment by inhibiting microglia-mediated inflammation through a potential NF-κB pathway-related mechanism, suggesting that EGCG can be used as a promising drug for the treatment of infrasound-induced CNS damage.The Journal of nutritional biochemistry 07/2014; · 4.29 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Disequilibrium of the cytokine network was reported to play an important role in the progression of chronic heart failure (CHF). Catechin exerts cardioprotection through treating many kinds of angiocardiopathy. However, the effects of catechin on CHF are currently unclear. Therefore, the main aim of this study was to investigate the efficacy of catechin on CHF rats as well as its relationship to immunoregulation. CHF was induced in rats by ligation of the abdominal aorta. Myocardial function was evaluated by left ventricular systolic pressure and left ventricular end-diastolic pressure. The cytokine level was measured by enzyme-linked immunosorbent assay. Th17 and Treg levels in peripheral blood and spleen were analyzed by flow cytometry. The results showed that catechin treatment (50, 100 mg/kg/day) markedly improved myocardial function in rats treated with abdominal aortic coarctation. Severity of myocardial dysfunction in CHF rats significantly correlated with serum values of interleukin-17 (IL-17)/IL-10. Further results indicated catechin obviously inhibited immune activation, regulated unbalanced levels of IL-17/IL-10, and reversed abnormal polarization of TH17 as well as Treg in peripheral blood and spleen. Taken together, oral administration of catechin effectively suppressed abdominal aorta ligation-induced CHF in rats, which was closely associated with its modulation on Th17 and Treg.Agents and Actions 04/2014; · 2.14 Impact Factor
Green tea EGCG, T cells, and T cell-mediated autoimmune diseasesq
Dayong Wua,⇑, Junpeng Wanga, Munkyong Paea,1, Simin Nikbin Meydania,b
aNutritional Immunology Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, United States
bDepartment of Pathology, Sackler Graduate School of Biochemical Sciences, Tufts University, Boston, MA 02111, United States
a r t i c l ei n f o
Available online 14 October 2011
a b s t r a c t
One of the proposed health benefits of consuming green tea is its protective effect on auto-
immune diseases. Research on the immunopathogenesis of autoimmune diseases has
made significant progression in the past few years and several key concepts have been
revised. T cells, particularly CD4+T helper (Th) cells, play a key role in mediating many
aspects of autoimmune diseases. Upon antigenic stimulation, naïve CD4+T cells proliferate
and differentiate into different effector subsets. Th1 and Th17 cells are the pro-inflamma-
tory subsets of Th cells responsible for inducing autoimmunity whereas regulatory T cells
(Treg) have an antagonistic effect. Green tea and its active ingredient, epigallocatechin-3-
gallate (EGCG), have been shown to improve symptoms and reduce the pathology in some
animal models of autoimmune diseases. Whether or not EGCG’s effect is mediated through
its impact on Th17 and Treg development has not been studied. We conducted a series of
studies to investigate EGCG’s effect on CD4+T cell proliferation and differentiation as well
as its impact on the development of autoimmune disease. We first observed that EGCG
inhibited CD4+T cell expansion in response to either polyclonal or antigen specific stimu-
lation. We then determined how EGCG affects naïve CD4+T cell differentiation and found
that it impeded Th1 and Th17 differentiation and prevented IL-6-induced inhibition on
Treg development. We further demonstrated that EGCG inhibited Th1 and Th17 differenti-
ation by downregulating their corresponding transcription factors (STAT1 and T-bet for
Th1, and STAT3 and RORct for Th17). These effects provide further explanation for previous
findings that administration of EGCG by gavage to experimental autoimmune encephalo-
myelitis (EAE) mice, an animal model for human multiple sclerosis (MS), reduced the clin-
encephalitogenic T cells. Upon further investigating the working mechanisms for EGCG’s
protective effect in the EAE model, we showed that dietary EGCG dose-dependently atten-
uated the disease’s severity. This protective effect of EGCG is associated with the sup-
pressed proliferation of autoreactive T cells, reduced production of pro-inflammatory
cytokines, decreased Th1 and Th17, and increased Treg populations in lymphoid tissues
and central nervous system. EGCG-induced shifts in CD4+T cell subsets in EAE mice are
accompanied by the corresponding changes in their regulator molecules. Recent studies
have also highlighted the critical role of Th17/Treg balance in the pathogenesis of rheuma-
toid arthritis (RA). EGCG has been shown to be anti-inflammatory and protective in several
studies using animal models of inflammatory arthritis, but research, at the best, only to
start looking into the mechanisms with a focus on T cells. Overall, future research should
fully incorporate the current progress in autoimmunity into the study design to expand the
0098-2997/$ - see front matter ? 2011 Elsevier Ltd. All rights reserved.
qSupported by USDA National Institute of Food and Agriculture grant 2010-65200-20360 (to D.W.) and USDA, Agriculture Research Service contract
#58-1950-7-707 (to S.N.M.).
⇑Corresponding author. Address: Nutritional Immunology Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University,
711 Washington Street, Boston, MA 02111, United States. Tel.: +1 617 556 3368; fax: +1 617 556 3224.
E-mail address: email@example.com (D. Wu).
1Current address: Cellular and Molecular Physiology Section, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02115, United States.
Molecular Aspects of Medicine 33 (2012) 107–118
Contents lists available at SciVerse ScienceDirect
Molecular Aspects of Medicine
journal homepage: www.elsevier.com/locate/mam
power of evaluating EGCG’s efficacy in treating autoimmune diseases. Data from human
studies are essentially absent and thus are urgently needed.
? 2011 Elsevier Ltd. All rights reserved.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
EGCG and T cell-mediated immune functions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
EGCG and T cell-mediated autoimmune diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
3.1.CD4+T subsets: differentiation, function, and regulation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
3.2.Effect of EGCG on CD4+T cell differentiation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
3.3.T cells and autoimmune diseases: the case of experimental autoimmune encephalomyelitis (EAE) . . . . . . . . . . . . . . . . 112
3.4.Effect of EGCG on EAE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
3.5. Role of T cells in pathogenesis of RA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
3.6.Effect of EGCG on RA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Acknowledgment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Increasing evidence supports the beneficial effects of consuming green tea in several aspects of health and disease. The
catechins present in high content in green tea are thought to be the major components responsible for green tea’s biological
functions. These catechins include epicatechin, epigallocatechin, epicatechin-3-gallate, and epigallocatechin-3-gallate
(EGCG). Among them, EGCG is the most biologically active and also the most abundant, accounting for 50–80% of the total
catechins in green tea. Thus, EGCG is used in the majority of green tea studies. This review highlights our knowledge and
current progress in the field of research on green tea and EGCG’s effect on immune cells, particularly T cells and the appli-
cation of their immunomodulating properties in preventing and alleviating T cell-mediated autoimmune diseases.
2. EGCG and T cell-mediated immune functions
The immune-modulating effect of EGCG proposed by the early studies was largely based on the altered lymphocyte pro-
liferation after in vitro supplementation with tea extracts or catechins. For example, Hu and colleagues showed that EGCG at
dose of 24 lg/ml (55 lM) and higher inhibited both B and T cell proliferation, but a greater effect was observed in T cells (Hu
et al., 1992). Similarly, other researchers reported that in vitro supplementation with green tea extracts inhibited lymphocyte
proliferation in response to T cell mitogen concanavalin A (Con A) (Wilasrusmee et al., 2002) and allogeneic stimulator cells
(Kim et al., 2007; Wilasrusmee et al., 2002). In support of these findings in murine lymphocytes, a study showed that green
tea extracts also inhibited production of neopterin, a marker for activation of cellular immunity, by human peripheral blood
mononuclear cells (PBMC) when stimulated with Con A (Zvetkova et al., 2001). While the data obtained from these in vitro
studies have provided useful information for defining the nature of the immune-modulating activity of EGCG, in the majority
of these studies, however, EGCG was administered at doses far exceeding physiologically relevant levels, i.e., achievable via
oral intake, which makes the extrapolation of the obtained results for potential, clinical application questionable.
Some recent studies have been conducted using the in vivo models, or the in vitro design that included using physiolog-
ically relevant concentrations of EGCG (<10 lM). For example, in an animal study, oral administration of 0.3% green tea pol-
yphenol solution containing 50–60% of EGCG was effective at suppressing transplant-reactive T cell immunity as
demonstrated by prolonged skin graft survival and decreased frequency of donor reactive interferon (IFN)-c-producing T
cells during graft rejection (Bayer et al., 2004). Recently, we have shown that in vitro supplementation with EGCG (2.5–
10 lM) dose-dependently inhibits Con A-induced splenocyte proliferation, T cell division, and cell cycle progression of T cells
(Wu et al., 2009a). This effect of EGCG is not due to apoptosis, and it is unrelated to the previously reported EGCG-induced
H2O2generation as no difference in H2O2generation was observed with the addition of EGCG at this range of concentrations
and furthermore, catalase did not prevent EGCG-induced inhibition (Wu et al., 2009a). Since suppressed T cell proliferation
by EGCG was observed under conditions in which T cell response was induced and measured in total splenocytes, lymph
node cells, or PBMC, all of which are present as a mixture of multiple cell types, we need to further determine whether this
effect of EGCG represents its direct effect on T cells. Furthermore, the in vitro results need to be validated under in vivo con-
ditions. In a subsequent study, we investigated: (1) the efficacy of in vivo supplementation with EGCG, (2) the direct effect of
EGCG (2.5–15 lM) on T cell function using purified T cells to exclude any indirect effect through impacting accessory cells,
and (3) the underlying mechanisms of EGCG-induced suppression on T cells (Pae et al., 2010a). The results showed that 0.3%
D. Wu et al./Molecular Aspects of Medicine 33 (2012) 107–118
EGCG for 6 wk was effective in reducing ex vivo T cell proliferation when stimulated with either Con A or anti-CD3/CD28.
These results confirm that dietary EGCG supplementation could achieve in vivo levels that would be adequate to suppress
T cells (Pae et al., 2010a). More definitive experiments with in vitro EGCG supplementation revealed that EGCG dose-depen-
dently inhibited anti-CD3/CD28-stimulated cell division in T cells with a more prominent effect on CD4+T cells than CD8+T
cells. Furthermore, in a model of antigen (Ag) (ovalbumin)-specific T cell proliferation in which purified T cells and antigen-
presenting cells (APC) were incubated with or without EGCG (10 lM) separately, we demonstrated that EGCG markedly re-
duced T cell proliferation by affecting both T cells and APC; however, the direct effect of EGCG on T cells was predominant
(Pae et al., 2010a).
Another important feature of T cells is their ability to generate cytokines that support and regulate T cell expansion, dif-
ferentiation, and effector function, and to regulate the functions of other immune cells, particularly MU and B cells. Studies
have provided evidence suggesting that EGCG may modulate T cell-derived cytokines. For example, the in vitro EGCG treat-
ment was shown to inhibit IL-2 production in response to allogenic stimulator cells (Kim et al., 2007), IL-2, TNF-a, and IFN-c
production in Staphylococcus enterotoxin B-stimulated PBMC (Watson et al., 2005), and IFN-c production in Con A-stimu-
lated splenocytes (Wu et al., 2009a), or anti-CD3/CD28-stimulated purified T cells or CD4+T cells (our unpublished data). In
contrast, other studies have reported that in vitro EGCG supplementation upregulates mRNA levels of Th1 cytokines (IL-2 and
IFN-c) and Th2 cytokines (IL-5 and IL-13) in Jurkat cells (Wu et al., 2009b) and increases IL-2 production in response to PMA/
phytohaemagglutinin in human PBMC (Lyu and Park, 2005). We further investigated the effect of EGCG on IL-2 production
and IL-2/IL-2R signaling in total T cells or naïve CD4+T cells isolated from mice and found that IL-2 levels were unchanged in
the cultures treated with EGCG for 24 h or shorter time but were elevated in the 48 h culture in a dose-dependent manner
((Pae et al., 2010a) and unpublished data). Combined with the unchanged IL-2 mRNA expression and decreased IL-2Ra
expression in EGCG-treated T cells, we speculated that the higher levels of IL-2 may be associated with reduced IL-2 inter-
nalization and utilization due to inhibited IL-2R expression by EGCG (Pae et al., 2010a). We further found that expression of
two other IL-2R subunits, b andc chains, were also inhibited by EGCG, and this reduced IL-2R expression was associated with
impaired IL-2R downstream signaling as determined by reduced STAT5 phosphorylation (our unpublished data).
T cell activation signaling through T cell receptor (TCR) is needed for IL-2 production and subsequent T cell expansion. Not
surprisingly, several studies have indicated that EGCG may interfere with the early signaling events of T cell activation,
including Zap70 kinase in Jurkat cells and thus, downstream signaling events such as linker for the activation of T cells, phos-
pholipase Cc1, extracellular signaling-regulated kinase, and MAP kinase activity as well as AP-1 activation (Shim et al.,
2008). Similarly, in vitro EGCG supplementation was shown to induce suppressor of cytokine signaling gene 1 expression
in human PBMC, which may be mediated by EGCG-induced activation of STAT5, as suggested by authors based on their
experiments using mouse splenic monocytes deficient in different STATs (Ripley et al., 2010). Since TCR activation through
two sequential signals (TCR signal and IL-2/IL-2R signal) drives T cells to enter the cell cycle leading to their rapid prolifer-
ation and differentiation into effector cells, the inhibitory effect of EGCG on T cell signaling suggests that EGCG may interrupt
the cell cycle progress. Indeed, we found that in vitro EGCG supplementation dose-dependently retarded the cell cycle pro-
gression of T cells as measured in either splenocytes (Wu et al., 2009a) or purified T cells (Pae et al., 2010a). Traverse of G0/
G1 and entry into S phase are known to be controlled by ordered activation of cyclin-dependent kinases (CDKs) (Sherr, 1996).
CDK activity is up-regulated by cyclins and down-regulated by CDK inhibitors. p27kip1is a powerful CDK inhibitor and a pri-
mary modulator of proliferative status. It functions to induce and maintain the cells in a quiescent state and its overexpres-
sion arrests cells in G1phase (Toyoshima and Hunter, 1994). IL-2 plays a critical role in inducing cell cycle progression of T
cells through down-regulation of p27kip1(Firpo et al., 1994; Nourse et al., 1994) while EGCG has been shown to induce cell
cycle arrest through increasing levels of p27kip1in human NK and T cell lines (Lu et al., 2006; Nam et al., 2001). Therefore,
EGCG may induce cell cycle arrest by affecting cell cycle related proteins through down-regulation of IL-2/IL-2R signaling or
other mechanisms yet to be elucidated. Considering all these results, it appears that EGCG is in general suppressive toward T
cell functions. This property of EGCG thus opens the door for its potential application in T cell-mediated autoimmune
3. EGCG and T cell-mediated autoimmune diseases
Autoimmunity is defined as a host’s dysregulated immune system that attacks its own tissues. A variety of autoimmune
diseases are the manifestations of autoimmune disorders in different systems, organs, and tissues. Etiology of autoimmune
diseases is not clear. For some of them, however, T cells clearly play a critical role in their pathogenesis. These diseases are
thus referred to as T cell-mediated autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis (MS), type 1
diabetes, inflammatory bowel disease (IBD), Sjogren’s syndrome, systemic lupus erythematosus, and psoriasis. There is no
cure for most autoimmune diseases, and commonly used therapies have limited efficacy and often various side effects.
In the development of autoimmune diseases, genetic predisposition is thought to be a key risk factor while environmental
factors are also shown to play a role. Nutrition represents a modifiable environmental factor, which could potentially have a
positive impact on autoimmune diseases. Results from a limited number of animal studies suggest that green tea and its ac-
tive ingredient, EGCG, might be effective in improving the symptoms and pathological conditions of autoimmune diseases.
However, the information is still very limited regarding this aspect. A great majority of the work in this field has been done
using various animal models but little is known about clinical application in humans. Studies also take a cell-based,
D. Wu et al./Molecular Aspects of Medicine 33 (2012) 107–118
experimental approach, primarily as an initial screening step to identify potential candidates or for further mechanistic
investigation following positive findings in the in vivo studies. The immunopathogenesis of T cell-mediated autoimmune dis-
eases is best characterized in MS and its murine model experimental autoimmune encephalomyelitis (EAE). Our own work
has focused on the effect of EGCG consumption on EAE as well as the underlying mechanisms. This review will thus devote
much attention to EAE as a representative of autoimmune disease models to exemplify the role of T cells in the development
of autoimmune diseases, the cellular and molecular regulation network involved, and the possible working mechanisms
underlying the action of EGCG. Additionally, we will also discuss RA, another autoimmune disease, because RA is of the most
common autoimmune diseases, and T cell involvement in its pathogenesis has clearly been identified. Further, the effect of
green tea and EGCG has been studied in RA more than in any other autoimmune disease. Results from animal studies suggest
a protective effect for green tea and EGCG.
Inflammation is a central event in autoimmune diseases, either as a primary innate response or as a subsequent reaction
to T cell activation. EGCG is widely viewed as an anti-inflammatory agent based on its inhibitory effect on inflammatory
mediators as well as their regulators, which has, in fact, been the focus of a majority of studies reported thus far. However,
the intention of this review is to discuss only those studies that demonstrate a T cell involvement.
3.1. CD4+T subsets: differentiation, function, and regulation
CD4+T cells play a central role in the body’s defense system due to their great impact on the function of B cells and cells in
the innate immune system. On the other hand, CD4+T cells are also well-recognized as key drivers in the development of
major T cell-mediated autoimmune diseases. As illustrated in Table 1 and Fig. 1, based on their unique cytokine profile
and main regulatory function, CD4+T cells can be further classified into at least four functionally distinct subsets, namely
Th1, Th2, Th17, and regulatory T (Treg) cells (Abbas et al., 1996; Bettelli et al., 2006; Mangan et al., 2006; Mosmann
et al., 1986; Mosmann and Coffman, 1989; Street and Mosmann, 1991; Veldhoen et al., 2006). Differentiation of naïve
CD4+T cells into these different effector cells is initiated by TCR engagement and co-stimulation in the presence of specific
cytokines produced by the innate immune system upon encountering particular pathogens. Development of Th1 is promoted
Features of CD4+T cell subsets.
CD4+T cell subset Priming
Transcription factor Effector cytokineFunctionRole in immunopathology
T-bet, STAT1, STAT4
IFN-c, IL-2, TNFa
IL-4, IL-5, IL-13
IL-17A/F, IL-21, IL-22,
Extracellular bacteria and fungi
Fig. 1. CD4+T cell differentiation and its regulation network. Activated naïve CD4+T cells can differentiate into different subsets under appropriate cytokine
milieu. Each subset of CD4+T cells is characterized by their specific cytokine profile. The differentiation process is controlled by the corresponding
regulation network mainly composed of involved signal transducers and downstream transcription factors. Interaction exists among different CD4+T cell
subsets at their development stage as well as in their function to regulate autoimmune response.
D. Wu et al./Molecular Aspects of Medicine 33 (2012) 107–118
by IL-12 and IL-18, Th2 by IL-4, Th17 by TGF-b plus IL-6 or IL-21, and Treg by TGF-b. Hallmark cytokines for Th1, Th2, and
Th17 are IFN-c, IL-4, and IL-17, respectively, and Treg cells are often identified as CD4+CD25+Foxp3+cells. Th1 cells are
mainly responsible for immunity to intracellular pathogens while Th2 cells target extracellular pathogens. The recently iden-
tified Th17 cells are believed to play a critical role in the clearance of extracellular bacteria and fungi, particularly those not
well defended by Th1 or Th2 immunity (Dong, 2006; Weaver et al., 2006, 2007). Treg cells function mainly to maintain self-
tolerance and regulate immune responses (Sakaguchi, 2004).
Abnormal activation of Th1 and Th17 cells and reduced function of Treg cells are associated with organ-specific autoim-
mune diseases while Th2 cells contribute primarily to allergy and asthma. As mentioned above, naïve CD4+T cells differen-
tiate into distinct subsets. Th1 polarization is mainly driven by IL-12 and synergized by IL-18 (Robinson et al., 1997;
Robinson and O’Garra, 2002), and the resulting increase in production of its signature cytokine IFN-c gives further positive
feedback. IL-4 is both a signature cytokine for and a driving factor in Th2 cell differentiation, which requires the involvement
of IL-2 (Cote-Sierra et al., 2004; Le Gros et al., 1990). Th17 differentiation is initiated by TGF-b and IL-6, and it is amplified by
IL-21. Th17 cell proliferation and stabilization are supported by IL-23 (Zhu and Paul, 2008). Treg can be both constitutively
present and induced under appropriate conditions, and thus it is further distinguished as natural (n)Treg and induced (i)Treg,
respectively. TGF-b is important for nTreg development (Liu et al., 2008), and it plays a key role in iTreg differentiation (Chen
et al., 2003). Given the duplicity of TGF-b in driving naïve Th cells to both Th17 and Treg, the presence of IL-6 appears to be
the decisive factor in differentiation of these two subsets, i.e., TGF-b for Treg and TGF-b plus IL-6 for Th17 (Bettelli et al.,
In addition to transcription factors common to T cell activation, some transcription factors have a specific effect in deter-
mining the fate of Th cells (see Fig. 1). Signal transducers and activators of transcription (STAT) can regulate Th cell differ-
entiation through the induction of these lineage-specific transcription factors. T-box protein expressed in T cells (T-bet) is
the master regulator for Th1 differentiation (Szabo et al., 2000). STAT1 is a transducer for IFN-c-induced T-bet activation
(Lighvani et al., 2001), and STAT4 is a transducer for IL-12 to amplify Th1 response (Thierfelder et al., 1996). GATA-3 is
the master regulator for Th2 differentiation, and STAT6 is the key transducer for IL-4-induced GATA-3 activation (Kurata
et al., 1999; Zhu et al., 2001). Retinoic acid receptor-related orphan receptor (ROR)ct is the master regulator for Th17 differ-
entiation, and STAT3 is the key transducer that mediates action of IL-6, IL-21, and IL-23 (Nurieva et al., 2007; Yang et al.,
2007). Foxp3 is a master transcription factor found in Treg cells, and thus it is used as the signature marker for Treg differ-
entiation. Cytokine TGF-b is key factor for Treg cell development and function. Several transducer molecules have been
shown to mediate the effect of TGF-b on Foxp3 expression (Bommireddy and Doetschman, 2007; Rubtsov and Rudensky,
2007; Zhou et al., 2008). SMAD proteins are intracellular TGF-b signal transducers, and SMAD3 mediates most actions of
TGF-b (Derynck et al., 1998; Feng and Derynck, 2005). TGF-b binds to its receptors (TGFbRII and I), which in turn phosphor-
ylate SMAD3. Phosphorylated SMAD3 forms a complex with SMAD4 (co-mediator SMAD) and translocates into the nucleus,
where they cooperate with sequence-specific transcription factors to regulate gene expression. Inhibitory SMAD (SMAD7)
inhibits TGF-b signaling by inducing TGFbR degradation (Di Guglielmo et al., 2003), and SMAD7 overexpression in T cells
prohibits induction of Foxp3 (Dominitzki et al., 2007).
There is a cross inhibition among different CD4+T cell lineages in their functions and during their differentiation. This
cross regulation is present at multiple layers, i.e., cytokines, transcription regulators, and master genes (Bettelli et al.,
2006; Dominitzki et al., 2007; Weaver et al., 2007; Zhu and Paul, 2008). In particular, the decision of antigen-stimulated cells
to differentiate into either Th17 or Treg cells mainly depends on the cytokine-regulated balance of RORct and Foxp3. It is
widely accepted that Th1 and Th17 cells promote and Treg cells mitigate development of autoimmune diseases (see below
for more details). Thus, development of naïve CD4+T cells into these subsets has become a target for drug therapy in auto-
immune diseases. Based on our results to be discussed later, green tea EGCG has the potential to decrease pathogenesis of
autoimmune diseases by influencing CD4+T cell differentiation.
3.2. Effect of EGCG on CD4+T cell differentiation
In our previous studies, we found that EGCG inhibited CD4+T cell proliferation and IFN-c production but that it did not
affect IL-4 and IL-10 production (Pae et al., 2010a). These results indicate that EGCG may specifically suppress Th1 response,
which may explain its reported protective effect in some T cell-mediated autoimmune diseases. Given the increasingly
emphasized importance of Th17 and Treg in the pathogenesis of autoimmune diseases and the absence of such information
in the published studies showing a protective effect of EGCG in autoimmune diseases, we tested if EGCG could affect CD4+T
cell differentiation in a manner that would explain its effect on autoimmune diseases. All the results reviewed below are
unpublished data, some of which were published in the conference abstract (Pae et al., 2010b). In our experiments, we acti-
vated purified naïve CD4+T cells in the presence of 10 lM EGCG and under the appropriate conditions that drive Th1, Th17,
and Treg polarizations, respectively. We found that induced differentiation of naïve CD4+T cells into Th1 was reduced by half
(60% vs. 31%) in the presence of EGCG. In accordance with this result, the expression of main signal transducer p-STAT1 and
master regulator T-bet were also reduced by EGCG. Likewise, naïve CD4+T cell differentiation into Th17 cells was reduced by
about 60% (18% vs. 7%) in the presence of EGCG, which coincided with a reduction in their main signal transducer p-STAT3
and master regulator RORct. On the other hand, EGCG did not affect nTreg cell population but slightly increased the fre-
quency of iTreg cells. More interestingly, addition of IL-6 reduced iTreg differentiation, and this reduction was greatly pre-
vented by EGCG. Based on these results, we conclude that EGCG downregulates Th1 and Th17 differentiation and
D. Wu et al./Molecular Aspects of Medicine 33 (2012) 107–118
upregulates iTreg differentiation. These findings may help us understand the protective effect of EGCG observed in several T
cell-mediated, autoimmune disease animal models.
3.3. T cells and autoimmune diseases: the case of experimental autoimmune encephalomyelitis (EAE)
Altered T cell responses play a key role in autoimmune pathologies. Typical disease manifestation is exemplified in MS
and RA. MS is a T cell-dependent, autoimmune inflammatory disease and EAE is a well-characterized rodent model for hu-
man MS. EAE is a highly reproducible and widely-used tool for studying T cell-mediated autoimmunity. EAE is typically in-
duced by immunizing susceptible strains with a component of myelin such as basic myelin protein (BMP), proteolipid
protein (PLP), or myelin oligodendrocyte glycoprotein (MOG), or a peptide derived from one of these proteins such as PLP
peptide139–151and MOG peptide35–55, emulsified in an adjuvant to generate strong T cell response. Development of EAE is
characterized as an ascending paralysis that begins from the tail, followed by manifesting in rear legs, and eventually pro-
gressing into forearms.
MS pathogenesis involves a process in which autoreactive myelin-specific CD4+T cells orchestrate their effector function
toward myelin sheath in the central nervous system (CNS) resulting in tissue destruction and thus, the loss of function (Ando
et al., 1989; Kuchroo et al., 2002; Merrill et al., 1992). Tissue inflammation precedes the clinical signs. EAE has long been
considered the prototypic Th1-mediated autoimmune disorder, which is associated with increased production and activity
of proinflammatory cytokines, predominantly IFN-c and other Th1 cytokines, by autoreactive T cells activated systemically
or at specific sites. IFN-c was found to be present in EAE lesions during active disease and its levels were reduced during
remission (Baker et al., 1991; Khoury et al., 1992). Th1 cells were able to transfer the disease while mice deficient in the tran-
scription factors important for Th1 differentiation were resistant to EAE development (Dardalhon et al., 2008). In the past
few years, rapid progress has been made in this field. In particular, compelling evidence has highlighted the importance
of newly defined Th17 cells, which may play a primary role in this model as well as in some other autoimmune diseases.
Some of the autoimmune responses formerly attributed to Th1 cells are now believed to be mediated by Th17 cells. Although
the Th1 centered theory in EAE and other autoimmune diseases has been challenged, the importance of Th1 cells in EAE con-
tinues to be emphasized by the investigators. For example, myelin-reactive Th1 devoid of contaminating Th17 cells were
shown to be highly pathogenic after transfer to normal recipient animals, and Th1 cells were highly capable of homing to
the CNS and orchestrating inflammation and cellular recruitment, which facilitated the entry of Th17 cells (O’Connor
et al., 2008). Additionally, some intervention agents ameliorate EAE symptoms and pathology through suppressing Th1 re-
sponse (Brahmachari and Pahan, 2007; Miyake et al., 2006; Ren et al., 2008). A recent study showed that adoptive transfer of
either Th1 or Th17 cells induced mouse EAE with similar clinical symptoms but distinct infiltration patterns of cells of innate
immunity, i.e., macrophages were dominant with adoptive Th1 transfer and neutrophils were dominant with Th17 and their
corresponding chemokine expression patterns (Kroenke et al., 2008). In a more recent study, adoptive transfer of either path-
ologic Th1 or Th17 cells could induce EAE, but with distinguishable characteristics in pathology and symptoms (Domingues
et al., 2010). Altogether, regardless of their relative importance and distinct roles (to be further elucidated), it is likely that
both Th1 and Th17 cells are main drivers in T cell-mediated autoimmune diseases.
Another important type of T cells involved in regulation of T cell-mediated autoimmune diseases is Treg cells, well-
summarized in a recent review (Buckner, 2010). The severity and mortality of actively-induced EAE in non-transgenic mice
were enhanced by treatment with anti-CD25 antibody following immunization while transfer of CD4+CD25+Treg cells from
naïve mice decreased the severity of active EAE (Zhang et al., 2004). Similarly, EAE-resistant B10.S mice had a higher
proportion of PLP139–151-reactive CD4+CD25+Treg cells, and depletion of CD4+CD25+Treg cells facilitated the expansion of
PLP139–151-reactive cells with production of Th1 cytokines in EAE-resistant B10.S mice (Reddy et al., 2004). Taken together,
these results suggest that a dysregulated balance in T cell subpopulations Th1, Th17, and Treg contributes to initiation of EAE
and thus, an agent that could impact this balance favorably might impede EAE development. After learning that EGCG sup-
presses CD4+T cell expansion and differentiation toward downregulating pro-inflammatory Th1 and Th17 and upregulating
anti-inflammatory Treg cells, we tested whether oral administration of EGCG could provide protection in an autoimmune
disease animal model.
3.4. Effect of EGCG on EAE
In the only published study on this topic, Aktas et al. (2004) found that administration of EGCG to EAE mice by gavage
(300 lg/mouse twice daily from the day of immunization on) reduced clinical symptoms, brain inflammation, and neuronal
damage. Draining lymph node (LN) cells from EGCG-treated mice had a lower proliferative response to the in vitro rechal-
lenge with immunization antigen PLP139–151and a lower production of TNF-a, but EGCG had no effect on IL-4 and IFN-c pro-
duction. The authors reported no effect of EGCG on Treg cells, defined as CD4+CD25+cells. However, given the fact that
activated CD4+T cells also express CD25 (IL-2Ra chain) and that the authors did not use the specific marker Foxp3 to identify
Treg cells, it is likely that the change in activated T cells might have masked real changes in Treg population. This study dem-
onstrated the efficacy of EGCG in improving EAE symptoms and provided evidence suggesting that the effect of EGCG was
mediated through suppression of T cell activity. Published prior to the introduction of Th17/Treg concept into immunopatho-
genesis, the study understandably provided limited mechanistic information. Taking advantage of the recent developments
in understanding pathogenesis of autoimmune immunity and using a multi-dose dietary supplementation design, we
D. Wu et al./Molecular Aspects of Medicine 33 (2012) 107–118
revisited this issue. In our recent study (Wang et al., 2011), we fed C57BL/6 mice EGCG (0%, 0.15%, 0.3%, and 0.6% in diet) for
30 d and then immunized them with specific antigen MOG35–55. EGCG dose-dependently attenuated the clinical symptoms
and pathology (leukocyte infiltration and demyelination) in the CNS and inhibited Ag-specific T cell proliferation and de-
layed-type hypersensitivity skin response induced by autoantigen MOG35–55. We further showed that EGCG reduced produc-
tion of pro-inflammatory cytokines IFN-c, IL-17, IL-6, IL-1b, IL-12, IL-23, and TNF-a, decreased Th1 and Th17, and increased
Treg populations in LN, spleen, and CNS. Moreover, EGCG inhibited expression of T-bet & RORct, master regulators for Th1
and Th17 differentiation, respectively, which is accordance with the reduced populations of both subsets in EGCG-treated
mice. The observed reduction in IL-6, IL-1b, IL-12, IL-23, and TNF-a production by EGCG treatment are also assumed to con-
tribute to both the alleviation of EAE and the change in composition of CD4+T cell subsets based on the information provided
below. IL-6 is a decisive factor in switching differentiation toward Th17 cells away from Treg conversion (Bettelli et al., 2006,
2007; Korn et al., 2008). IL-1b and IL-6 (Acosta-Rodriguez et al., 2007) or IL-23 and IL-1b (Wilson et al., 2007) are essential for
Th17 development; IL-12 is the master cytokine in driving Th1 differentiation (Hsieh et al., 1993; Seder et al., 1993); TNF-a, a
Th1 cytokine, promotes EAE symptoms and pathology (Begolka et al., 1998; Issazadeh et al., 1995, 1998; Kuroda and
Shimamoto, 1991). All these cytokines are upregulated in human MS and murine EAE (Acosta-Rodriguez et al., 2007; Imitola
et al., 2005; Sospedra and Martin, 2005; Wilson et al., 2007). This study also found that EGCG treatment reduced plasma lev-
els of soluble intercellular adhesion molecule-1 (sICAM-1), and CD4+T cells expressing C-C chemokine receptor 6 (CCR6) in
EAE mice. These results may explain the reduced T cell infiltration into the CNS in EGCG-treated EAE mice because (1) adhe-
sion molecules play an important role in the migration of immune cells into the CNS, (2) MS patients have increased serum
levels of soluble ICAM-1 (Rieckmann et al., 1993; Sharief et al., 1993), (3) ICAM-1 is more important than other adhesion
molecules in promoting pathological cell infiltration into the CNS and development of EAE (Bullard et al., 2007; Kebir
et al., 2009), and (4). CCR6 is essential for the first wave of autoreactive Th17 migrating into the uninflamed CNS by inter-
acting with its only ligand CCL20, constitutively expressed in the epithelial cells of the choroid plexus (Reboldi et al., 2009).
CCL20 is probably not responsible for reduced cell infiltration by EGCG because CCL20 expression in the CNS was not
changed by EGCG treatment. It appears that the effect of EGCG on EAE is more therapeutic rather than preventive in nature
because starting treatment 30 d before immunization delayed onset and reduced severity of disease but did not reduce
the disease incidence. Starting EGCG supplementation during the induction phase (day 7 post-immunization) and effector
phase (day 12 post-immunization) also similarly attenuated the symptoms except that EGCG no longer delayed onset when
the treatment started during the effector phase. These findings support the proposed beneficial effect of EGCG on autoim-
mune diseases and more importantly, they shed light on the key mechanisms underlying this effect of EGCG.
3.5. Role of T cells in pathogenesis of RA
RA is a chronic inflammatory disease characterized by the activation of synovial tissue and its invasion into cartilage and
bone resulting in the progressive destruction of joints. It is likely that RA is not simply a single disease but rather, it may
represent a spectrum of distinct clinical entities (Cope, 2008; Imboden, 2009). Although RA is considered an autoimmune
disease, as yet there is no consistent evidence defining the responsible autoantigens. RA is widely accepted as a T cell-
mediated autoimmune disorder given that increasing evidence supports the notion that T cells participate in the etiology
and pathogenesis of RA. Large numbers of T cells in diffused or clustered form are present in synovial biopsies of RA patients
(Duke et al., 1982). The animal models for studying RA, such as collagen-induced or adjuvant-induced arthritis, are clearly T
cell-dependent. As discussed earlier in this review, recent progress in the research of CD4+T cell subsets has greatly revised
our understanding of the immunopathology of autoimmune disease development. Similar to our discussion of the current
view on the pathogenesis of MS/EAE, the long standing Th1/Th2 paradigm has been challenged and the roles of Th17 and
Treg in RA are now being increasingly emphasized as new evidence emerges. For example, IL-17 is found to be increased
in blood and synovial fluid of RA patients (Chabaud et al., 1999; Hwang and Kim, 2005; Ziolkowska et al., 2000). IL-17, whose
pathogenic role has been characterized in studies on animal models of inflammatory arthritis, is shown to be responsible for
priming collagen-specific T cells and collagen-specific IgG2a production. Collagen-induced arthritis (CIA) was markedly sup-
pressed in IL-17 deficient mice (Nakae et al., 2003), whereas blocking IL-17 with neutralizing Ab (Lubberts et al., 2004) or
soluble IL-17 receptor (Bush et al., 2002) was able to alleviate the disease. IL-17 can also induce production of inflammatory
cytokines (IL-1b, TNF-a, IL-6, IL-23), chemokines (CXC-1, -2, -5, -8, CCL2, and CCL20), matrix metalloproteinases, nitric oxide,
and receptor activator of NF-jB (RANK)/RANK ligand, thus promoting inflammatory infiltration and cartilage damage (Sarkar
and Fox, 2010). The importance of IL-17 in human RA is supported by some but not all studies, suggesting that IL-17 and
Th17 cells are proinflammatory in at least a subset of RA patients (Imboden, 2009).
As mentioned earlier, Treg cells maintain immune tolerance and play a critical role in preventing autoimmunity. In RA,
however, results appear paradoxical as RA patients have larger numbers of Treg cells in their synovial fluid (Cao et al.,
2006; Mottonen et al., 2005) or in some cases their peripheral blood (Han et al., 2008); some other studies also reported see-
ing more Treg cells in synovial fluid than in peripheral blood (Cao et al., 2004; van Amelsfort et al., 2004). Thus it appears that
synovial inflammation persists despite the presence of Treg cells. One explanation for this phenomenon is that identification
of Treg cells based on CD25 expression might have limitation. For example, it may have included the activated CD4+T cells
that express CD25 as IL-2Ra chain. Another explanation is that Treg cells are enriched in synovial fluid as a result of pref-
erential trafficking to the joints because Treg cells express appropriate chemokine receptors (Oh et al., 2010). The lack of
quantitative abnormality of Treg cells in RA patients has led people to the question whether these cells are functionally
D. Wu et al./Molecular Aspects of Medicine 33 (2012) 107–118
abnormal. Although still a topic for debate, some evidence supports a reduced functionality of Treg cells in RA patients. For
example, Treg cells isolated from RA patients exhibit a compromised suppressor function (Ehrenstein et al., 2004; Valencia
et al., 2006). Compared to healthy controls, RA Treg cells had similar (Ehrenstein et al., 2004) or reduced (Valencia et al.,
2006) function in suppressing CD4+CD25?T cell proliferation, but they were unable to inhibit TNF-a and IFN-c production
by CD4+CD25?T cells.
Th17 and Treg cells are mutually antagonistic in autoimmunity and their differentiations are also reciprocally regulated.
Further, studies have shown that Treg cells can be converted to Th17 cells (Radhakrishnan et al., 2008; Xu et al., 2007). IL-6 is
a clearly defined, key factor in tipping the balance toward Th17 and away from Treg as discussed earlier. In addition to the
observation that TNF-a downregulates Treg generation and reduces their suppressive functions (as mentioned above), TNF-a
is both up and down stream to IL-17 regulation and can synergize with IL-17 to induce synovial inflammation and tissue
destruction (Lubberts et al., 2005). Thus, IL-6 and TNF-a have become therapeutic targets for controlling RA and other auto-
immune diseases (Feldmann et al., 2005; KEYSTONE and WARE, 2010; Nishimoto, 2006; Nishimoto et al., 2004). As shown in
the previous studies, given its suppressive effect on inflammatory cytokines including IL-6 and TNF-a, green tea or EGCG is
presumed to possess therapeutic value in RA. However, as can be seen below, only a limited number of studies on this sub-
ject exist, and they barely addressed the involvement of Th17/Treg cells.
3.6. Effect of EGCG on RA
In line with the T cell-suppressive and anti-inflammatory properties of EGCG, animal studies using the experimental
arthritis model suggest that green tea/EGCG may have a protective effect on RA. Haqqi et al. were the first to report that
green tea polyphenols (the largest part being EGCG) given in drinking water to mice reduced the incidence of CIA together
with a reduced expression of IFN-c, TNF-a, and cyclooxygenase(COX)-2, as well as total IgG and type II collagen-specific IgG
(Ab) in arthritic joints (Haqqi et al., 1999). In a more recent study (Kim et al., 2008), Kim and colleagues fed Lewis rats GTP
extract in drinking water (8 or 12 g/L) for 1–3 wk before injecting them with heat-killed Mycobacterium tuberculosis H37Ra
to generate adjuvant-induced arthritis (AA). The authors found that the rats in both 8 and 12 g/L GTP diet groups for 2 or
3 wk had significantly reduced severity of arthritis, but this effect was greater in 8 g/L group than in 12 g/L group. This
improvement in symptoms was accompanied by decreased serum levels of Ab against the disease-related antigen Bhsp65
as well as increased IL-10 production and decreased IL-17 mRNA expression in lymph node cells after in vitro challenge with
Bhsp65. T cell proliferation and production of IFN-c and IL-4 in response to Bhsp65 were not different between GTP and con-
trol rats. The increased IL-10, decreased IL-17, and decreased anti-Bhsp65 Ab were suggested by the authors to be the main
mechanisms for the protective effect of green tea polyphenols against AA. Given the very limited outcome measurements
presented in this study, the mechanisms’ picture is far from complete. Since this study did not analyze the subsets of
CD4+T cells, it is difficult to assess if the effect of GTP is mediated through favorably altered CD4+T cell differentiation.
The best extrapolation is that the observed reduction in IL-17 mRNA to certain degree might have reflected a reduced num-
ber of Th17 cells, similarly but with even lesser certainty, the increased IL-10 might be partly attributed to an upregulated
Treg population. The observation that GPT failed to suppress expansion of pathologic T cells is in contradiction to what has
been seen in the case of EAE. The protective effect of green tea in arthritis is also studied in green tea’s effect on chemokines
and their receptors, the factors that promote inflammation and joint destruction in RA development. Green tea extract
administration (200 mg/kg/day p.o.) was shown to ameliorate AA in rats. The authors found a decrease in MCP-1/CCL2
and GROa/CXCL1 levels and an increase in CCR-1, -2, -5, and CXCR1 receptor expression in the joints of green tea extract-
administered rats (Marotte et al., 2010). Altered production of inflammatory cytokine IL-6 may be another factor that
mediated the protective effect of EGCG on RA. The pathologic role of IL-6 in RA development has been well documented
(Nishimoto, 2006). RA patients have higher levels of IL-6 in their serum and synovial fluid, and this elevated IL-6 is correlated
with disease activity (Houssiau et al., 1988). IL-6 has become a pharmacological target for controlling RA (Nishimoto, 2006;
Nishimoto et al., 2004). As mentioned above, IL-6 drives Th17 differentiation and inhibits Treg differentiation and thus, mod-
ulating IL-6 activity is expected to affect autoimmune diseases such as MS and RA. Along this line, Ahmed et al. reported that
EGCG administration (100 mg/kg, i.p. daily) to mice during the onset (day 7–17 after induction) of AA reduced IL-6 levels in
serum and joints, with concomitant amelioration of rat AA. EGCG treatment was also found to decrease expression of mem-
brane-bound gp130 protein (a component of IL-6 receptors for transmitting IL-6 signal) in the joint homogenates and to en-
hance synthesis of soluble gp130, an endogenous inhibitor of IL-6 signaling and trans-signaling. Furthermore, EGCG
treatment inhibited IL-6/soluble IL-6 receptor-induced matrix metalloproteinase-2 activity in RA synovial fibroblasts and
in joint homogenates via upregulated soluble gp130, which seems to indicate a mechanism for arthritis inhibited by EGCG
4. Concluding remarks
Evidence supporting health benefits of green tea consumption in multiple body systems and a variety of diseases has been
accumulating including its applications for prevention and/or alleviation of autoimmune diseases. Information along this
line is almost exclusively obtained from studies that utilize several established animal models that share a varied degree
of similarity to the represented human diseases in their pathogeneses and/or clinical manifestations. The results thus far
D. Wu et al./Molecular Aspects of Medicine 33 (2012) 107–118
are promising but not without controversy. In this regard, there is a definite paucity of mechanistic insight concerning the
effect of EGCG. Although research in the immunopathology of autoimmune diseases has progressed rapidly recently and no-
vel concepts continue to emerge publications on the role of EGCG in autoimmunity have not kept pace with the new progress
in autoimmunity research. Based on the current views of the pathogenesis of autoimmune disease and together with what
we have learned about the possible cellular and molecular targets for EGCG action, we are convinced that EGCG has strong
therapeutic potential in treating autoimmune diseases. It is anticipated that new studies are under way and that we will
soon see a significant update in the field. Finally, it is important to mention that there is an obvious lack of human study
data. While animal models are useful tools for us to obtain valuable information, it is well-recognized and should always
be in mind that animal models have limitations in mimicking human diseases and furthermore, differences in EGCG bioavail-
ability and biopotency also exists between humans and experimental animals. Therefore, future intervention studies in hu-
mans are urgently needed in order to clinically validate the therapeutic value of EGCG’s effect on autoimmune diseases.
The authors would like to thank Stephanie Marco for her assistance in the preparation of the manuscript.
Abbas, A.K., Murphy, K.M., Sher, A., 1996. Functional diversity of helper T lymphocytes. Nature 383 (6603), 787–793.
Acosta-Rodriguez, E.V., Napolitani, G., Lanzavecchia, A., Sallusto, F., 2007. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for
the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8 (9), 942–949.
Aktas, O., Prozorovski, T., Smorodchenko, A., Savaskan, N.E., Lauster, R., Kloetzel, P.M., Infante-Duarte, C., Brocke, S., Zipp, F., 2004. Green tea
epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 173 (9),
Ando, D.G., Clayton, J., Kono, D., Urban, J.L., Sercarz, E.E., 1989. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE)
are of the Th-1 lymphokine subtype. Cell Immunol. 124 (1), 132–143.
Baker, D., O’Neill, J.K., Turk, J.L., 1991. Cytokines in the central nervous system of mice during chronic relapsing experimental allergic encephalomyelitis. Cell
Immunol. 134 (2), 505–510.
Bayer, J., Gomer, A., Demir, Y., Amano, H., Kish, D.D., Fairchild, R., Heeger, P.S., 2004. Effects of green tea polyphenols on murine transplant-reactive T cell
immunity. Clin. Immunol. 110 (1), 100–108.
Begolka, W.S., Vanderlugt, C.L., Rahbe, S.M., Miller, S.D., 1998. Differential expression of inflammatory cytokines parallels progression of central nervous
system pathology in two clinically distinct models of multiple sclerosis. J. Immunol. 161 (8), 4437–4446.
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Weiner, H.L., Kuchroo, V.K., 2006. Reciprocal developmental pathways for the generation of
pathogenic effector TH17 and regulatory T cells. Nature 441 (7090), 235–238.
Bettelli, E., Oukka, M., Kuchroo, V.K., 2007. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8 (4), 345–350.
Bommireddy, R., Doetschman, T., 2007. TGFbeta1 and Treg cells: alliance for tolerance. Trends Mol. Med. 13 (11), 492–501.
Brahmachari, S., Pahan, K., 2007. Sodium benzoate, a food additive and a metabolite of cinnamon, modifies T cells at multiple steps and inhibits adoptive
transfer of experimental allergic encephalomyelitis. J. Immunol. 179 (1), 275–283.
Buckner, J.H., 2010. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol.
10 (12), 849–859.
Bullard, D.C., Hu, X., Schoeb, T.R., Collins, R.G., Beaudet, A.L., Barnum, S.R., 2007. Intercellular adhesion molecule-1 expression is required on multiple cell
types for the development of experimental autoimmune encephalomyelitis. J. Immunol. 178 (2), 851–857.
Bush, K.A., Farmer, K.M., Walker, J.S., Kirkham, B.W., 2002. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with
interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 46 (3), 802–805.
Cao, D., Borjesson, O., Larsson, P., Rudin, A., Gunnarsson, I., Klareskog, L., Malmstrom, V., Trollmo, C., 2006. FOXP3 identifies regulatory CD25bright CD4+ T
cells in rheumatic joints. Scand. J. Immunol. 63 (6), 444–452.
Cao, D., van Vollenhoven, R., Klareskog, L., Trollmo, C., Malmstrom, V., 2004. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients
with chronic rheumatic disease. Arthritis Res. Ther. 6 (4), R335–346.
Chabaud, M., Durand, J.M., Buchs, N., Fossiez, F., Page, G., Frappart, L., Miossec, P., 1999. Human interleukin-17: A T cell-derived proinflammatory cytokine
produced by the rheumatoid synovium. Arthritis Rheum. 42 (5), 963–970.
Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N., McGrady, G., Wahl, S.M., 2003. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+
regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198 (12), 1875–1886.
Cope, A.P., 2008. T cells in rheumatoid arthritis. Arthritis Res. Ther. 10 (Suppl. 1), S1.
Cote-Sierra, J., Foucras, G., Guo, L., Chiodetti, L., Young, H.A., Hu-Li, J., Zhu, J., Paul, W.E., 2004. Interleukin 2 plays a central role in Th2 differentiation. Proc.
Natl. Acad. Sci. USA 101 (11), 3880–3885.
Dardalhon, V., Korn, T., Kuchroo, V.K., Anderson, A.C., 2008. Role of Th1 and Th17 cells in organ-specific autoimmunity. J. Autoimmun. 31 (3), 252–256.
Derynck, R., Zhang, Y., Feng, X.H., 1998. Smads: transcriptional activators of TGF-beta responses. Cell 95 (6), 737–740.
Di Guglielmo, G.M., Le Roy, C., Goodfellow, A.F., Wrana, J.L., 2003. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat. Cell
Biol. 5 (5), 410–421.
Domingues, H.S., Mues, M., Lassmann, H., Wekerle, H., Krishnamoorthy, G., 2010. Functional and pathogenic differences of Th1 and Th17 cells in
experimental autoimmune encephalomyelitis. PLoS One 5 (11), e15531.
Dominitzki, S., Fantini, M.C., Neufert, C., Nikolaev, A., Galle, P.R., Scheller, J., Monteleone, G., Rose-John, S., Neurath, M.F., Becker, C., 2007. Cutting edge: trans-
signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J. Immunol. 179 (4), 2041–2045.
Dong, C., 2006. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat. Rev. Immunol. 6 (4), 329–333.
Duke, O., Panayi, G.S., Janossy, G., Poulter, L.W., 1982. An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the
synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin. Exp. Immunol. 49 (1), 22–30.
Ehrenstein, M.R., Evans, J.G., Singh, A., Moore, S., Warnes, G., Isenberg, D.A., Mauri, C., 2004. Compromised function of regulatory T cells in rheumatoid
arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200 (3), 277–285.
Feldmann, M., Brennan, F.M., Foxwell, B.M.J., Taylor, P.C., Williams, R.O., Maini, R.N., 2005. Anti-TNF therapy: Where have we got to in 2005? J. Autoimmun.
25 (Suppl. 1), 26–28.
Feng, X.H., Derynck, R., 2005. Specificity and versatility in tgf-beta signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659–693.
Firpo, E.J., Koff, A., Solomon, M.J., Roberts, J.M., 1994. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes.
Mol. Cell Biol. 14 (7), 4889–4901.
D. Wu et al./Molecular Aspects of Medicine 33 (2012) 107–118
Han, G.M., O’Neil-Andersen, N.J., Zurier, R.B., Lawrence, D.A., 2008. CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with
rheumatoid arthritis. Cell Immunol. 253 (1–2), 92–101.
Haqqi, T.M., Anthony, D.D., Gupta, S., Ahmad, N., Lee, M.S., Kumar, G.K., Mukhtar, H., 1999. Prevention of collagen-induced arthritis in mice by a polyphenolic
fraction from green tea. Proc. Natl. Acad. Sci. USA 96 (8), 4524–4529.
Houssiau, F.A., Devogelaer, J.P., Van Damme, J., de Deuxchaisnes, C.N., Van Snick, J., 1988. Interleukin-6 in synovial fluid and serum of patients with
rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 31 (6), 784–788.
Hsieh, C.S., Macatonia, S.E., Tripp, C.S., Wolf, S.F., O’Garra, A., Murphy, K.M., 1993. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-
induced macrophages. Science 260 (5107), 547–549.
Hu, Z.Q., Toda, M., Okubo, S., Hara, Y., Shimamura, T., 1992. Mitogenic activity of (-)epigallocatechin gallate on B-cells and investigation of its structure-
function relationship. Int. J. Immunopharmacol. 14 (8), 1399–1407.
Hwang, S.Y., Kim, H.Y., 2005. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol. Cells 19 (2), 180–
Imboden, J.B., 2009. The immunopathogenesis of rheumatoid arthritis. Annu. Rev. Pathol. 4, 417–434.
Imitola, J., Chitnis, T., Khoury, S.J., 2005. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol. Ther. 106 (2), 163–177.
Issazadeh, S., Ljungdahl, A., Hojeberg, B., Mustafa, M., Olsson, T., 1995. Cytokine production in the central nervous system of Lewis rats with experimental
autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor
necrosis factor beta. J. Neuroimmunol. 61 (2), 205–212.
Issazadeh, S., Navikas, V., Schaub, M., Sayegh, M., Khoury, S., 1998. Kinetics of expression of costimulatory molecules and their ligands in murine relapsing
experimental autoimmune encephalomyelitis in vivo. J. Immunol. 161 (3), 1104–1112.
Kebir, H., Ifergan, I., Alvarez, J.I., Bernard, M., Poirier, J., Arbour, N., Duquette, P., Prat, A., 2009. Preferential recruitment of interferon-gamma-expressing
TH17 cells in multiple sclerosis. Ann. Neurol. 66 (3), 390–402.
KEYSTONE, E.C., WARE, C.F., 2010. Tumor necrosis factor and anti-tumor necrosis factor therapies. J. Rheum. 85, 27–39.
Khoury, S.J., Hancock, W.W., Weiner, H.L., 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune
encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta,
interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176 (5), 1355–1364.
Kim, H.R., Rajaiah, R., Wu, Q.-L., Satpute, S.R., Tan, M.T., Simon, J.E., Berman, B.M., Moudgil, K.D., 2008. Green tea protects rats against autoimmune arthritis
by modulating disease-related immune events. J. Nutr. 138 (11), 2111–2116.
Kim, J.Y., Kina, T., Iwanaga, Y., Noguchi, H., Matsumura, K., Hyon, S.H., 2007. Tea polyphenol inhibits allostimulation in mixed lymphocyte culture. Cell
Transplant. 16 (1), 75–83.
Korn, T., Mitsdoerffer, M., Croxford, A.L., Awasthi, A., Dardalhon, V.A., Galileos, G., Vollmar, P., Stritesky, G.L., Kaplan, M.H., Waisman, A., Kuchroo, V.K., Oukka,
M., 2008. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci.
USA 105 (47), 18460–18465.
Kroenke, M.A., Carlson, T.J., Andjelkovic, A.V., Segal, B.M., 2008. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS
chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205 (7), 1535–1541.
Kuchroo, V.K., Anderson, A.C., Waldner, H., Munder, M., Bettelli, E., Nicholson, L.B., 2002. T cell response in experimental autoimmune encephalomyelitis
(EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu. Rev. Immunol. 20, 101–123.
Kurata, H., Lee, H.J., O’Garra, A., Arai, N., 1999. Ectopic expression of activated Stat6 induces the expression of Th2-specific cytokines and transcription
factors in developing Th1 cells. Immunity 11 (6), 677–688.
Kuroda, Y., Shimamoto, Y., 1991. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J. Neuroimmunol. 34 (2–3),
Le Gros, G., Ben-Sasson, S.Z., Seder, R., Finkelman, F.D., Paul, W.E., 1990. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4
are required for in vitro generation of IL-4-producing cells. J. Exp. Med. 172 (3), 921–929.
Lighvani, A.A., Frucht, D.M., Jankovic, D., Yamane, H., Aliberti, J., Hissong, B.D., Nguyen, B.V., Gadina, M., Sher, A., Paul, W.E., O’Shea, J.J., 2001. T-bet is rapidly
induced by interferon-gamma in lymphoid and myeloid cells. Proc. Natl. Acad. Sci. USA 98 (26), 15137–15142.
Liu, Y., Zhang, P., Li, J., Kulkarni, A.B., Perruche, S., Chen, W., 2008. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+
regulatory T cells. Nat. Immunol. 9 (6), 632–640.
Lu, M., Dou, Q.P., Kitson, R.P., Smith, D.M., Goldfarb, R.H., 2006. Differential effects of proteasome inhibitors on cell cycle and apoptotic pathways in human
YT and Jurkat cells. J. Cell Biochem. 97 (1), 122–134.
Lubberts, E., Koenders, M.I., Oppers-Walgreen, B., van den Bersselaar, L., Coenen-de Roo, C.J., Joosten, L.A., van den Berg, W.B., 2004. Treatment with a
neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and
bone erosion. Arthritis Rheum. 50 (2), 650–659.
Lubberts, E., Koenders, M.I., van den Berg, W.B., 2005. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models.
Arthritis Res. Ther. 7 (1), 29–37.
Lyu, S.Y., Park, W.B., 2005. Production of cytokine and NO by RAW 264.7 macrophages and PBMC in vitro incubation with flavonoids. Arch Pharm. Res. 28
Mangan, P.R., Harrington, L.E., O’Quinn, D.B., Helms, W.S., Bullard, D.C., Elson, C.O., Hatton, R.D., Wahl, S.M., Schoeb, T.R., Weaver, C.T., 2006. Transforming
growth factor-beta induces development of the T(H)17 lineage. Nature 441 (7090), 231–234.
Marotte, H., Ruth, J.H., Campbell, P.L., Koch, A.E., Ahmed, S., 2010. Green tea extract inhibits chemokine production, but up-regulates chemokine receptor
expression, in rheumatoid arthritis synovial fibroblasts and rat adjuvant-induced arthritis. Rheumatology 49 (3), 467–479.
Merrill, J.E., Kono, D.H., Clayton, J., Ando, D.G., Hinton, D.R., Hofman, F.M., 1992. Inflammatory leukocytes and cytokines in the peptide-induced disease of
experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc. Natl. Acad. Sci. USA 89 (2), 574–578.
Miyake, M., Sasaki, K., Ide, K., Matsukura, Y., Shijima, K., Fujiwara, D., 2006. Highly oligomeric procyanidins ameliorate experimental autoimmune
encephalomyelitis via suppression of Th1 immunity. J. Immunol. 176 (10), 5797–5804.
Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A., Coffman, R.L., 1986. Two types of murine helper T cell clone. I. Definition according to profiles of
lymphokine activities and secreted proteins. J. Immunol. 136 (7), 2348–2357.
Mosmann, T.R., Coffman, R.L., 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev.
Immunol. 7, 145–173.
Mottonen, M., Heikkinen, J., Mustonen, L., Isomaki, P., Luukkainen, R., Lassila, O., 2005. CD4+ CD25+ T cells with the phenotypic and functional
characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin. Exp. Immunol. 140 (2), 360–367.
Nakae, S., Nambu, A., Sudo, K., Iwakura, Y., 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171
Nam, S., Smith, D.M., Dou, Q.P., 2001. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem. 276 (16),
Nishimoto, N., 2006. Interleukin-6 in rheumatoid arthritis. Curr. Opin. Rheumatol. 18 (3), 277–281.
Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J., Kishimoto, T., 2004. Treatment of rheumatoid
arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50 (6), 1761–
Nourse, J., Firpo, E., Flanagan, W.M., Coats, S., Polyak, K., Lee, M.H., Massague, J., Crabtree, G.R., Roberts, J.M., 1994. Interleukin-2-mediated elimination of the
p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372 (6506), 570–573.
D. Wu et al./Molecular Aspects of Medicine 33 (2012) 107–118
Nurieva, R., Yang, X.O., Martinez, G., Zhang, Y., Panopoulos, A.D., Ma, L., Schluns, K., Tian, Q., Watowich, S.S., Jetten, A.M., Dong, C., 2007. Essential autocrine
regulation by IL-21 in the generation of inflammatory T cells. Nature 448 (7152), 480–483.
O’Connor, R.A., Prendergast, C.T., Sabatos, C.A., Lau, C.W., Leech, M.D., Wraith, D.C., Anderton, S.M., 2008. Cutting edge: Th1 cells facilitate the entry of Th17
cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 181 (6), 3750–3754.
Oh, S., Rankin, A.L., Caton, A.J., 2010. CD4+CD25+ regulatory T cells in autoimmune arthritis. Immunol. Rev. 233 (1), 97–111.
Pae, M., Ren, Z., Meydani, M., Shang, F., Meydani, S.N., Wu, D., 2010a. Epigallocatechin-3-gallate directly suppresses T cell proliferation through impaired IL-
2 utilization and cell cycle progression. J. Nutr. 140 (8), 1509–1515.
Pae, M., Ren, Z., Meydani, S.N., Wu, D., 2010b. Green tea EGCG suppresses specific antigen driven T cell response and affects CD4+ T cell differentiation.
FASEB J. 24 (1_MeetingAbstracts), 326.8.
Radhakrishnan, S., Cabrera, R., Schenk, E.L., Nava-Parada, P., Bell, M.P., Van Keulen, V.P., Marler, R.J., Felts, S.J., Pease, L.R., 2008. Reprogrammed FoxP3+ T
regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J. Immunol. 181 (5), 3137–3147.
Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., Sallusto, F., 2009. C-C chemokine
receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10 (5), 514–523.
Reddy, J., Illes, Z., Zhang, X., Encinas, J., Pyrdol, J., Nicholson, L., Sobel, R.A., Wucherpfennig, K.W., Kuchroo, V.K., 2004. Myelin proteolipid protein-specific
CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 101 (43), 15434–
Ren, Y., Lu, L., Guo, T.B., Qiu, J., Yang, Y., Liu, A., Zhang, J.Z., 2008. Novel immunomodulatory properties of berbamine through selective down-regulation of
STAT4 and action of IFN-gamma in experimental autoimmune encephalomyelitis. J. Immunol. 181 (2), 1491–1498.
Rieckmann, P., Nunke, K., Burchhardt, M., Albrecht, M., Wiltfang, J., Ulrich, M., Felgenhauer, K., 1993. Soluble intercellular adhesion molecule-1 in
cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J. Neuroimmunol. 47 (2), 133–140.
Ripley, B.J., Fujimoto, M., Serada, S., Ohkawara, T., Nishikawa, T., Terabe, F., Matsukawa, Y., Stephanou, A., Knight, R.A., Isenberg, D.A., Latchman, D.S.,
Kishimoto, T., Naka, T., 2010. Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expression. Int. Immunol. 22
Robinson, D., Shibuya, K., Mui, A., Zonin, F., Murphy, E., Sana, T., Hartley, S.B., Menon, S., Kastelein, R., Bazan, F., O’Garra, A., 1997. IGIF does not drive Th1
development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 7 (4), 571–581.
Robinson, D.S., O’Garra, A., 2002. Further checkpoints in Th1 development. Immunity 16 (6), 755–758.
Rubtsov, Y.P., Rudensky, A.Y., 2007. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat. Rev. Immunol. 7 (6), 443–453.
Sakaguchi, S., 2004. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev.
Immunol. 22, 531–562.
Sarkar, S., Fox, D.A., 2010. Targeting IL-17 and Th17 cells in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 36 (2), 345–366.
Seder, R.A., Gazzinelli, R., Sher, A., Paul, W.E., 1993. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and
diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90 (21), 10188–10192.
Sharief, M.K., Noori, M.A., Ciardi, M., Cirelli, A., Thompson, E.J., 1993. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with
active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage. J. Neuroimmunol. 43 (1–2), 15–21.
Sherr, C.J., 1996. Cancer cell cycles. Science 274 (5293), 1672–1677.
Shim, J.H., Choi, H.S., Pugliese, A., Lee, S.Y., Chae, J.I., Choi, B.Y., Bode, A.M., Dong, Z., 2008. (?)-Epigallocatechin gallate regulates CD3-mediated T cell receptor
signaling in leukemia through the inhibition of ZAP-70 kinase. J. Biol. Chem. 283 (42), 28370–28379.
Sospedra, M., Martin, R., 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23, 683–747.
Street, N.E., Mosmann, T.R., 1991. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 5 (2), 171–177.
Szabo, S.J., Kim, S.T., Costa, G.L., Zhang, X., Fathman, C.G., Glimcher, L.H., 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100
Thierfelder, W.E., van Deursen, J.M., Yamamoto, K., Tripp, R.A., Sarawar, S.R., Carson, R.T., Sangster, M.Y., Vignali, D.A., Doherty, P.C., Grosveld, G.C., Ihle, J.N.,
1996. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382 (6587), 171–174.
Toyoshima, H., Hunter, T., 1994. P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78 (1), 67–74.
Valencia, X., Stephens, G., Goldbach-Mansky, R., Wilson, M., Shevach, E.M., Lipsky, P.E., 2006. TNF downmodulates the function of human CD4+CD25hi T-
regulatory cells. Blood 108 (1), 253–261.
van Amelsfort, J.M., Jacobs, K.M., Bijlsma, J.W., Lafeber, F.P., Taams, L.S., 2004. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the
presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 50 (9), 2775–2785.
Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M., Stockinger, B., 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo
differentiation of IL-17-producing T cells. Immunity 24 (2), 179–189.
Wang, J., Ren, Z., Xu, Y., Xiao, S., Meydani, S.N., Wu, D., 2011. Epigallocatechin-3-gallate ameliorates experimental autoimmune encephalomyelitis by
altering balance among CD4+ T cell subsets. Am. J. Pathol., in press.
Watson, J.L., Vicario, M., Wang, A., Moreto, M., McKay, D.M., 2005. Immune cell activation and subsequent epithelial dysfunction by Staphylococcus
enterotoxin B is attenuated by the green tea polyphenol (?)-epigallocatechin gallate. Cell Immunol. 237 (1), 7–16.
Weaver, C.T., Harrington, L.E., Mangan, P.R., Gavrieli, M., Murphy, K.M., 2006. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24
Weaver, C.T., Hatton, R.D., Mangan, P.R., Harrington, L.E., 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev.
Immunol. 25, 821–852.
Wilasrusmee, C., Kittur, S., Siddiqui, J., Bruch, D., Wilasrusmee, S., Kittur, D.S., 2002. In vitro immunomodulatory effects of ten commonly used herbs on
murine lymphocytes. J. Altern. Complem. Med. 8 (4), 467–475.
Wilson, N.J., Boniface, K., Chan, J.R., McKenzie, B.S., Blumenschein, W.M., Mattson, J.D., Basham, B., Smith, K., Chen, T., Morel, F., Lecron, J.C., Kastelein, R.A.,
Cua, D.J., McClanahan, T.K., Bowman, E.P., de Waal Malefyt, R., 2007. Development, cytokine profile and function of human interleukin 17-producing
helper T cells. Nat. Immunol. 8 (9), 950–957.
Wu, D., Guo, Z., Ren, Z., Guo, W., Meydani, S.N., 2009a. Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling.
Free Radic. Biol. Med. 47 (5), 636–643.
Wu, H., Zhu, B., Shimoishi, Y., Murata, Y., Nakamura, Y., 2009b. (?)-Epigallocatechin-3-gallate induces up-regulation of Th1 and Th2 cytokine genes in Jurkat
T cells. Arch Biochem. Biophys. 483 (1), 99–105.
Xu, L., Kitani, A., Fuss, I., Strober, W., 2007. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the
absence of exogenous TGF-beta. J. Immunol. 178 (11), 6725–6729.
Yang, X.O., Panopoulos, A.D., Nurieva, R., Chang, S.H., Wang, D., Watowich, S.S., Dong, C., 2007. STAT3 regulates cytokine-mediated generation of
inflammatory helper T cells. J. Biol. Chem. 282 (13), 9358–9363.
Zhang, X., Koldzic, D.N., Izikson, L., Reddy, J., Nazareno, R.F., Sakaguchi, S., Kuchroo, V.K., Weiner, H.L., 2004. IL-10 is involved in the suppression of
experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int. Immunol. 16 (2), 249–256.
Zhou, L., Lopes, J.E., Chong, M.M., Ivanov, I.I., Min, R., Victora, G.D., Shen, Y., Du, J., Rubtsov, Y.P., Rudensky, A.Y., Ziegler, S.F., Littman, D.R., 2008. TGF-beta-
induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453 (7192), 236–240.
Zhu, J., Guo, L., Watson, C.J., Hu-Li, J., Paul, W.E., 2001. Stat6 is necessary and sufficient for IL-4’s role in Th2 differentiation and cell expansion. J. Immunol.
166 (12), 7276–7281.
Zhu, J., Paul, W.E., 2008. CD4 T cells: fates, functions, and faults. Blood 112 (5), 1557–1569.
D. Wu et al./Molecular Aspects of Medicine 33 (2012) 107–118
Ziolkowska, M., Koc, A., Luszczykiewicz, G., Ksiezopolska-Pietrzak, K., Klimczak, E., Chwalinska-Sadowska, H., Maslinski, W., 2000. High levels of IL-17 in
rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 164 (5), 2832–2838.
Zvetkova, E., Wirleitner, B., Tram, N.T., Schennach, H., Fuchs, D., 2001. Aqueous extracts of Crinum latifolium (L.) and Camellia sinensis show
immunomodulatory properties in human peripheral blood mononuclear cells. Int. Immunopharmacol. 1 (12), 2143–2150.
D. Wu et al./Molecular Aspects of Medicine 33 (2012) 107–118